Nektar Therapeutics (NKTR) Non Operating Income (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Non Operating Income of -$4.0 million for Q1 2026, down 120.07% year-over-year from $20.1 million in Q1 2025, and up 42.65% quarter-over-quarter from -$7.0 million in Q4 2025.
Nektar Therapeutics (NKTR) Non Operating Income (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$4.0 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 120.07% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$17.6 million (down 21.91% YoY), while the FY2025 annual figure was -$15.4 million, down 9.88% from the prior year.
- Non Operating Income for Q1 2026 stood at -$4.0 million, up from -$7.0 million in the prior quarter.
- The five-year high for Non Operating Income was $26.3 million in Q1 2022, with the low at -$8.6 million in Q4 2023.
- The 5-year median for Non Operating Income is -$3.2 million (2025), against an average of -$2.0 million.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income surged 295.01% in 2022, then tumbled 346.14% in 2024.
- Nektar Therapeutics' Non Operating Income stood at -$4.1 million in 2022, then plunged by 110.97% to -$8.6 million in 2023, then gained by 14.55% to -$7.3 million in 2024, then climbed by 4.21% to -$7.0 million in 2025, then jumped by 42.65% to -$4.0 million in 2026.
- Business Quant data shows NKTR's Non Operating Income at -$4.0 million in Q1 2026, -$7.0 million in Q4 2025, and -$3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -4.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.04 Mn |
| Dec 31, 2025 | -7.04 Mn |
| Sep 30, 2025 | -3.35 Mn |
| Jun 30, 2025 | -3.17 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | -7.35 Mn |
| Sep 30, 2024 | -2.70 Mn |
| Jun 30, 2024 | -2.54 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | -8.60 Mn |
| Sep 30, 2023 | -1.03 Mn |
| Jun 30, 2023 | -570,000.00 |
| Mar 31, 2023 | -2.37 Mn |
| Dec 31, 2022 | -4.08 Mn |
| Sep 30, 2022 | -4.90 Mn |
| Jun 30, 2022 | -6.13 Mn |
| Mar 31, 2022 | 26.29 Mn |
| Dec 31, 2021 | -32.74 Mn |
| Sep 30, 2021 | -16.00 Mn |
| Jun 30, 2021 | -14.96 Mn |